<p>Spyglass Pharma, Inc.（纳斯达克代码：SGP - 获取免费报告）在目前覆盖该公司的五家券商中获得了 “适度买入” 的共识评级，Marketbeat.com 报道。一位股票研究分析师对该股票给予了持有推荐，四位分析师则给予了买入推荐。在过去一年中，发布报告的券商对该股票的平均一年目标价为 47.00 美元。</p>
<p>获取 <strong>Spyglass Pharma</strong> 的提醒：</p>
<p>几家研究公司对 SGP 进行了评论。Leerink Partners 在周二的一份研究报告中将 Spyglass Pharma 的股票评级下调至 “市场表现”。Zacks Research 在周三的一份研究报告中将 Spyglass Pharma 的评级上调至 “持有”。花旗集团在周二的一份报告中开始覆盖 Spyglass Pharma。他们对该股票设定了 “买入” 评级和 42.00 美元的目标价。华尔街 Zen 在 2 月 17 日的研究报告中将 Spyglass Pharma 的评级上调至 “持有”。最后，Stifel Nicolaus 在周二的一份报告中开始覆盖 Spyglass Pharma。他们对该公司发布了 “买入” 评级和 42.00 美元的目标价。</p>
<p><strong>查看我们关于 Spyglass Pharma 的最新研究报告</strong></p>
<h2>Spyglass Pharma 的内部买卖</h2>
<p>在其他新闻中，董事 Ra Capital Management, L.P.于 2 月 9 日星期一收购了 3,690,000 股 Spyglass Pharma 的股票。该股票的平均收购成本为每股 16.00 美元，总交易额为 59,040,000.00 美元。完成购买后，该董事持有公司 5,966,439 股股票，价值 95,463,024 美元。这代表了他们持股比例的 162.10% 的增长。此次收购已在向 SEC 提交的文件中披露，相关文件可通过此链接访问。</p>
<h2>Spyglass Pharma 股价下跌 1.0%</h2>
<p>SGP 的股票在周五开盘价为 26.42 美元。Spyglass Pharma 的 12 个月低点为 20.16 美元，12 个月高点为 32.44 美元。</p>
<h2>关于 Spyglass Pharma</h2>
<p>（获取免费报告）</p>
<p>我们是一家晚期生物制药公司，致力于通过长期有效的药物递送改变慢性眼病患者的治疗模式。我们的使命是通过开发耐用的药物递送解决方案，显著改善慢性眼病患者的生活，使患者和外科医生在长期疾病控制和视力保护方面充满信心。我们的主要产品候选者，Bimatoprost 药物垫-IOL 系统（BIM-IOL 系统），由新型专有药物垫与我们的人工晶状体（IOL）相结合，旨在在常规白内障手术中植入，以降低患有开角型青光眼（OAG）或眼压增高（OHT）患者的眼内压（IOP）。</p>
<h2>另请参阅</h2>
<ul>
<li>五只我们更看好的股票，胜过 Spyglass Pharma</li>
<li>银是新石油——而世界正在枯竭</li>
<li>BNZI 在 Zacks 买入中脱颖而出。盈利势头和分析师升级一致</li>
<li>1,500 家银行刚刚将您的银行账户交给了美联储</li>
<li>埃隆·马斯克的 1 万亿美元 AI IPO</li>
<li>[如何] 用 100 美元投资 SpaceX 的 IPO！</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Spyglass Pharma 吗？</h2>
<p>在您考虑 Spyglass Pharma 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Spyglass Pharma 并不在名单上。</p>
<p>虽然 Spyglass Pharma 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Spyglass Pharma, Inc.（纳斯达克代码：SGP）获得了五家券商的 “适度买入” 共识评级。一位分析师给予其持有评级，而四位分析师则给予买入推荐。平均一年目标价为 47.00 美元。最近的报告包括 Leerink Partners 将其评级下调至 “市场表现”，以及花旗集团给予 “买入” 评级，目标价为 42.00 美元。董事 Ra Capital Management 以每股 16.00 美元的价格收购了 369 万股，增加了 162.10% 的持股比例。SGP 股票开盘价为 26.42 美元，12 个月的价格区间为 20.16 美元至 32.44 美元</p>

<p>Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) has earned a consensus rating of &#34;Moderate Buy&#34; from the five brokerages that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $47.00.</p>
<div class="lb-trans"><p>Spyglass Pharma, Inc.（纳斯达克代码：SGP - 获取免费报告）在目前覆盖该公司的五家券商中获得了 “适度买入” 的共识评级，Marketbeat.com 报道。一位股票研究分析师对该股票给予了持有推荐，四位分析师则给予了买入推荐。在过去一年中，发布报告的券商对该股票的平均一年目标价为 47.00 美元。</p>
</div><p>Get <strong>Spyglass Pharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Spyglass Pharma</strong> 的提醒：</p>
</div><p>Several research firms have commented on SGP. Leerink Partners downgraded shares of Spyglass Pharma to a &#34;market perform&#34; rating in a research report on Tuesday. Zacks Research raised Spyglass Pharma to a &#34;hold&#34; rating in a research report on Wednesday. Citigroup initiated coverage on Spyglass Pharma in a report on Tuesday. They set a &#34;buy&#34; rating and a $42.00 price objective on the stock. Wall Street Zen raised Spyglass Pharma to a &#34;hold&#34; rating in a research note on Tuesday, February 17th. Finally, Stifel Nicolaus started coverage on Spyglass Pharma in a report on Tuesday. They issued a &#34;buy&#34; rating and a $42.00 target price for the company.</p>
<div class="lb-trans"><p>几家研究公司对 SGP 进行了评论。Leerink Partners 在周二的一份研究报告中将 Spyglass Pharma 的股票评级下调至 “市场表现”。Zacks Research 在周三的一份研究报告中将 Spyglass Pharma 的评级上调至 “持有”。花旗集团在周二的一份报告中开始覆盖 Spyglass Pharma。他们对该股票设定了 “买入” 评级和 42.00 美元的目标价。华尔街 Zen 在 2 月 17 日的研究报告中将 Spyglass Pharma 的评级上调至 “持有”。最后，Stifel Nicolaus 在周二的一份报告中开始覆盖 Spyglass Pharma。他们对该公司发布了 “买入” 评级和 42.00 美元的目标价。</p>
</div><p><strong>Check Out Our Latest Research Report on Spyglass Pharma</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Spyglass Pharma 的最新研究报告</strong></p>
</div><h2>Insider Buying and Selling at Spyglass Pharma</h2>
<div class="lb-trans"><h2>Spyglass Pharma 的内部买卖</h2>
</div><p>In other news, Director Ra Capital Management, L.P. acquired 3,690,000 shares of Spyglass Pharma stock in a transaction dated Monday, February 9th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $59,040,000.00. Following the completion of the purchase, the director owned 5,966,439 shares of the company's stock, valued at $95,463,024. This represents a 162.10% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.</p>
<div class="lb-trans"><p>在其他新闻中，董事 Ra Capital Management, L.P.于 2 月 9 日星期一收购了 3,690,000 股 Spyglass Pharma 的股票。该股票的平均收购成本为每股 16.00 美元，总交易额为 59,040,000.00 美元。完成购买后，该董事持有公司 5,966,439 股股票，价值 95,463,024 美元。这代表了他们持股比例的 162.10% 的增长。此次收购已在向 SEC 提交的文件中披露，相关文件可通过此链接访问。</p>
</div><h2>Spyglass Pharma Trading Down 1.0%</h2>
<div class="lb-trans"><h2>Spyglass Pharma 股价下跌 1.0%</h2>
</div><p>Shares of SGP opened at $26.42 on Friday. Spyglass Pharma has a 12 month low of $20.16 and a 12 month high of $32.44.</p>
<div class="lb-trans"><p>SGP 的股票在周五开盘价为 26.42 美元。Spyglass Pharma 的 12 个月低点为 20.16 美元，12 个月高点为 32.44 美元。</p>
</div><h2>About Spyglass Pharma</h2>
<div class="lb-trans"><h2>关于 Spyglass Pharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).</p>
<div class="lb-trans"><p>我们是一家晚期生物制药公司，致力于通过长期有效的药物递送改变慢性眼病患者的治疗模式。我们的使命是通过开发耐用的药物递送解决方案，显著改善慢性眼病患者的生活，使患者和外科医生在长期疾病控制和视力保护方面充满信心。我们的主要产品候选者，Bimatoprost 药物垫-IOL 系统（BIM-IOL 系统），由新型专有药物垫与我们的人工晶状体（IOL）相结合，旨在在常规白内障手术中植入，以降低患有开角型青光眼（OAG）或眼压增高（OHT）患者的眼内压（IOP）。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Spyglass Pharma</li>
<li>Silver Is the New Oil—And the World’s Running Dry</li>
<li>BNZI stands out as a Zacks Buy. Earnings momentum and analyst upgrades align</li>
<li>1,500 Banks Just Handed the Fed Your Bank Account</li>
<li>Elon Musk’s $1 Quadrillion AI IPO</li>
<li>[How To] Invest Pre-IPO In SpaceX With $100!</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Spyglass Pharma</li>
<li>银是新石油——而世界正在枯竭</li>
<li>BNZI 在 Zacks 买入中脱颖而出。盈利势头和分析师升级一致</li>
<li>1,500 家银行刚刚将您的银行账户交给了美联储</li>
<li>埃隆·马斯克的 1 万亿美元 AI IPO</li>
<li>[如何] 用 100 美元投资 SpaceX 的 IPO！</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=SGP"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Spyglass Pharma Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Spyglass Pharma 吗？</h2>
</div><p>Before you consider Spyglass Pharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Spyglass Pharma 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyglass Pharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Spyglass Pharma 并不在名单上。</p>
</div><p>While Spyglass Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Spyglass Pharma 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Spyglass Pharma, Inc.（纳斯达克股票代码：SGP）获得分析师一致推荐为 “适度买入”